HC Wainwright Estimates Immunic’s Q4 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at HC Wainwright issued their Q4 2024 earnings estimates for Immunic in a research note issued to investors on Monday, November 25th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.25) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.93) per share.

Several other equities analysts also recently commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. B. Riley assumed coverage on shares of Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Leerink Partners reiterated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Immunic currently has a consensus rating of “Buy” and an average target price of $11.80.

Immunic Trading Down 3.4 %

Shares of IMUX opened at $1.14 on Tuesday. The company has a market cap of $102.69 million, a price-to-earnings ratio of -0.93 and a beta of 1.88. Immunic has a 1-year low of $0.97 and a 1-year high of $2.11. The company’s fifty day simple moving average is $1.38 and its 200 day simple moving average is $1.34.

Insider Buying and Selling at Immunic

In other news, Director Richard Alan Rudick bought 87,300 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now directly owns 87,300 shares in the company, valued at approximately $100,395. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunic

Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC purchased a new stake in Immunic in the 1st quarter worth about $9,266,000. Vanguard Group Inc. increased its holdings in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the last quarter. Ikarian Capital LLC increased its holdings in Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.